| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-07 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.16 | 2e-06 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.17 | 7e-06 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.13 | 4e-05 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.14 | 5e-05 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.14 | 8e-05 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0001 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0003 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0003 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |